Tags

Type your tag names separated by a space and hit enter

Long-term results of Artecoll injection laryngoplasty for patients with unilateral vocal fold motion impairment: safety and clinical efficacy.
Arch Otolaryngol Head Neck Surg. 2008 May; 134(5):490-6.AO

Abstract

OBJECTIVE

To determine the long-term clinical efficacy and safety of injections of Artecoll, a soft-tissue filler consisting of a suspension of polymethyl methacrylate microspheres in a 3.5% solution of bovine collagen, into a vocal fold for managing glottal insufficiency secondary to unilateral vocal fold motion impairment.

DESIGN

Single-institution retrospective study.

SETTING

A single tertiary care teaching hospital of Sungkyunkwan University School of Medicine.

PATIENTS

Ninety-six patients with unilateral vocal fold motion impairment.

INTERVENTIONS

Percutaneous Artecoll injection laryngoplasty under local anesthesia.

MAIN OUTCOME MEASURES

Acoustic, aerodynamic, and stroboscopic analyses were performed before injection and 1 week and 3, 6, and 12 months after injection. Two speech-language pathologists performed the perceptual assessment, and we used the subjective rating of hoarseness by the patients.

RESULTS

The maximal phonation time, shimmer (amplitude variation), jitter (frequency variation), and ratio of noise to harmonic showed significant improvement 3 months after injection; these improvements were maintained 12 months after injection (P < .05). The GRBAS scale (overall grade of hoarseness, roughness, breathiness, asthenicity, and strain) grades and subjective patient-rated scores of hoarseness improved from 1 week after injection, and the improvements were maintained 12 months after injection (P < .05). We observed no significant early or delayed adverse events.

CONCLUSION

Injection laryngoplasty with Artecoll is a safe, useful, and durable treatment option for the management of glottal insufficiency secondary to unilateral vocal fold motion impairment.

Authors+Show Affiliations

Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-Dong, Gangnam-Gu, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18490569

Citation

Min, Jin-Young, et al. "Long-term Results of Artecoll Injection Laryngoplasty for Patients With Unilateral Vocal Fold Motion Impairment: Safety and Clinical Efficacy." Archives of Otolaryngology--head & Neck Surgery, vol. 134, no. 5, 2008, pp. 490-6.
Min JY, Hong SD, Kim K, et al. Long-term results of Artecoll injection laryngoplasty for patients with unilateral vocal fold motion impairment: safety and clinical efficacy. Arch Otolaryngol Head Neck Surg. 2008;134(5):490-6.
Min, J. Y., Hong, S. D., Kim, K., & Son, Y. I. (2008). Long-term results of Artecoll injection laryngoplasty for patients with unilateral vocal fold motion impairment: safety and clinical efficacy. Archives of Otolaryngology--head & Neck Surgery, 134(5), 490-6. https://doi.org/10.1001/archotol.134.5.490
Min JY, et al. Long-term Results of Artecoll Injection Laryngoplasty for Patients With Unilateral Vocal Fold Motion Impairment: Safety and Clinical Efficacy. Arch Otolaryngol Head Neck Surg. 2008;134(5):490-6. PubMed PMID: 18490569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term results of Artecoll injection laryngoplasty for patients with unilateral vocal fold motion impairment: safety and clinical efficacy. AU - Min,Jin-Young, AU - Hong,Sang-Duk, AU - Kim,Kwhanmien, AU - Son,Young-Ik, PY - 2008/5/21/pubmed PY - 2008/6/6/medline PY - 2008/5/21/entrez SP - 490 EP - 6 JF - Archives of otolaryngology--head & neck surgery JO - Arch Otolaryngol Head Neck Surg VL - 134 IS - 5 N2 - OBJECTIVE: To determine the long-term clinical efficacy and safety of injections of Artecoll, a soft-tissue filler consisting of a suspension of polymethyl methacrylate microspheres in a 3.5% solution of bovine collagen, into a vocal fold for managing glottal insufficiency secondary to unilateral vocal fold motion impairment. DESIGN: Single-institution retrospective study. SETTING: A single tertiary care teaching hospital of Sungkyunkwan University School of Medicine. PATIENTS: Ninety-six patients with unilateral vocal fold motion impairment. INTERVENTIONS: Percutaneous Artecoll injection laryngoplasty under local anesthesia. MAIN OUTCOME MEASURES: Acoustic, aerodynamic, and stroboscopic analyses were performed before injection and 1 week and 3, 6, and 12 months after injection. Two speech-language pathologists performed the perceptual assessment, and we used the subjective rating of hoarseness by the patients. RESULTS: The maximal phonation time, shimmer (amplitude variation), jitter (frequency variation), and ratio of noise to harmonic showed significant improvement 3 months after injection; these improvements were maintained 12 months after injection (P < .05). The GRBAS scale (overall grade of hoarseness, roughness, breathiness, asthenicity, and strain) grades and subjective patient-rated scores of hoarseness improved from 1 week after injection, and the improvements were maintained 12 months after injection (P < .05). We observed no significant early or delayed adverse events. CONCLUSION: Injection laryngoplasty with Artecoll is a safe, useful, and durable treatment option for the management of glottal insufficiency secondary to unilateral vocal fold motion impairment. SN - 1538-361X UR - https://www.unboundmedicine.com/medline/citation/18490569/Long_term_results_of_Artecoll_injection_laryngoplasty_for_patients_with_unilateral_vocal_fold_motion_impairment:_safety_and_clinical_efficacy_ L2 - https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/archotol.134.5.490 DB - PRIME DP - Unbound Medicine ER -